ArticleAnnals of the rheumatic diseases2007
Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjogren's syndrome.
Article in Annals of the rheumatic diseases, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 142 citations in OpenAlex.
- Serum immunoglobulin free light chain levels in systemic autoimmune rheumatic diseases.Clinical and experimental immunology · 2020Trial
- Serum immunoglobulin free light chains and post-transplant lymphoproliferative disorder among allogeneic hematopoietic stem cell transplant recipients.Bone marrow transplantation · 2015Trial
- Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2011Trial
- Kappa free light chain concentration in serum is reduced after CD20-depletion with ocrelizumab.Neurological research and practice · 2025Article
- B Cell-Derived and Non-B Cell-Derived Free Light Chains: From Generation to Biological and Pathophysiological Roles.International journal of molecular sciences · 2025Review
- Derangements of immunological proteins in HIV-associated diffuse large B-cell lymphoma: the frequency and prognostic impact.Frontiers in cellular and infection microbiology · 2024Article
- Free Light ChainsInternational journal of molecular sciences · 2023Review
- Combined serum free light chain predicts prognosis in acute kidney injury following cardiovascular surgery.Renal failure · 2022Article
- Article
- Gut mycobiome dysbiosis contributes to the development of hypertension and its response to immunoglobulin light chains.Frontiers in immunology · 2022Article
- Hematological and Genetic Markers in the Rational Approach to Patients With HCV Sustained Virological Response With or Without Persisting Cryoglobulinemic Vasculitis.Hepatology (Baltimore, Md.) · 2021Article
- Cell Population Data and Serum Polyclonal Immunoglobulin Free Light Chains in the Assessment of COVID-19 Severity.Viruses · 2021Article
- Immune-Related Urine Biomarkers for the Diagnosis of Lupus Nephritis.International journal of molecular sciences · 2021Review
- Rheumatologic diseases impact the risk of progression of MGUS to overt multiple myeloma.Blood advances · 2021Article
- Air Pollution and Polyclonal Elevation of Serum Free Light Chains: An Assessment of Adaptive Immune Responses in the Prospective Heinz Nixdorf Recall Study.Environmental health perspectives · 2021Article
- Idiopathic membranous nephropathy in a patient diagnosed with IgG4-related disease: A case report.Medicine · 2020Article
- High κ free light chain is a potential biomarker for double seronegative and ocular myasthenia gravis.Neurology(R) neuroimmunology & neuroinflammation · 2020Article
- Determination of serum free light chains as a marker of systemic lupus flare.Clinical rheumatology · 2020Article
- Comparative Proteomic Analysis of Serum from Pigs Experimentally Infected withPathogens (Basel, Switzerland) · 2020Article
- Serum markers of B-cell activation in pregnancy during late gestation, delivery, and the postpartum period.American journal of reproductive immunology (New York, N.Y. : 1989) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundB cell activation may result in an increased secretion of immunoglobulin free light chains (FLCs) in autoimmune diseases.
objectiveTo analyse serum FLC levels in patients with rheumatoid arthritis and in those with primary Sjögren's syndrome (pSS). PATIENTS AND
methodsBlood samples were collected from 80 healthy blood donors, 50 patients with rheumatoid arthritis and 139 patients with pSS. Serum FLC level was measured using a new quantitative immunoassay.
resultsMean (standard error (SE)) serum kappa and lambda FLC levels were significantly higher in patients with rheumatoid arthritis and in those with pSS than in controls (kappa : 18.9 (1.1) and 16.3 (1.4) v 10.5 (0.4) mg/l, p<0.001 and p = 0.001, respectively; lambda: 16.7 (1.2) and 19.3 (1.5) v 11.6 (0.6) mg/l, p<0.001 for both). 18 (36%) patients with rheumatoid arthritis and 31 (22.3%) patients with pSS had abnormal serum FLC levels (increased kappa or lambda levels and abnormal ratio of kappa:lambda). Serum kappa and lambda levels were correlated with other B cell activation markers in both diseases. FLC levels increased with disease activity, because, unlike total gammaglobulin and immunoglobulin G levels, they were significantly correlated with Disease Activity Score 28 in patients with rheumatoid arthritis (p = 0.004 for kappa, p = 0.05 for lambda) and with extraglandular involvement in pSS (p = 0.01 for kappa, p = 0.04 for lambda).
conclusionFLC levels are increased and correlate with disease activity in patients with rheumatoid arthritis and in those with pSS, two diseases in which increased risk of lymphoma could result from persistent B cell activation and disease activity. Further studies are required to determine whether FLC assessment could represent a relevant biomarker for response to treatment (especially B cell depletion) and for the risk of lymphoma in autoimmune diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.